Koers IMV Inc. Toronto S.E.
Aandelen
IMV
CA44974L3011
Biotechnologie & Medisch Onderzoek
Omzet 2021 | - | Omzet 2022 | - | Marktkapitalisatie | 30,6 mln. 41,83 mln. 28,62 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2021 | -36 mln. -49,21 mln. -33,67 mln. | Nettowinst (verlies) 2022 | -38 mln. -51,94 mln. -35,54 mln. | EV/omzet 2021 | - |
Nettoliquiditeiten 2021 | 18,96 mln. 25,92 mln. 17,73 mln. | Nettoschuld 2022 | 7,67 mln. 10,49 mln. 7,18 mln. | EV/omzet 2022 | - |
K/w-verhouding 2021 |
-2,47
x | K/w-verhouding 2022 |
-0,53
x | Werknemers | 63 |
Dividendrendement 2021 * |
-
| Dividendrendement 2022 |
-
| Vrij verhandelbaar | 99,93% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Andrew Hall
CEO | Chief Executive Officer | - | 10-11-20 |
Brittany Davison
DFI | Director of Finance/CFO | - | - |
Chief Operating Officer | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Chairman | 58 | 01-07-20 | |
Kyle Kuvalanka
BRD | Director/Board Member | 56 | 01-04-21 |
Markus Warmuth
BRD | Director/Board Member | 53 | 06-11-18 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+1,51% | 42,75 mld. | |
+49,22% | 41,61 mld. | |
+8,57% | 41,34 mld. | |
-12,36% | 26,59 mld. | |
+8,92% | 25,49 mld. | |
-25,13% | 18,12 mld. | |
+29,17% | 12,24 mld. | |
-3,12% | 11,76 mld. | |
+6,35% | 11 mld. |